Conveners
[LH5] Latest advances in cancer science and medicine: From basic to clinical applications
- Reinhard Buettner (University Cologne Institute of Pathology)
Description
This session will serve as the focal point of the cancer research community, bringing
together scientists, clinicians, other health care professionals, survivors, patients, and
advocates to share the most recent advances in cancer science and medicine.
When the results are being translated from basic research to clinical application, one cannot
stress enough the importance of cooperation between academia and industry, which is very
much related to the theme of EKC2023.
It will highlight the work of the best minds in cancer research from institutions all over
Europe and Korea, ranging from population science and prevention to cancer biology,
translational, and clinical studies, survivorship, and advocacy.
Anaplastic lymphoma kinase (ALK) gene rearrangement, representing 3 - 7% of NSCLC, was identified as an oncogenic driver in 2007 [1]. It typically comprises younger patients with never or light smoking history [1,2]. The labs of Choi and Buettner have made significant contributions in profiling this molecular subtype as their institutions have one of the largest collections of this rare entity...
Near-infrared fluorescence-guided surgery using cancer-specific tracers is a promising approach to balance the radicality and quality of life after surgery. Carcinoembryonic antigen (CEA) is a potential target due to its high expression in various digestive cancers, including gastric cancer (GC). This study aims to assess the feasibility of the anti-CEA chimeric monoclonal antibody-dye...
The nongenetic mechanisms required to sustain malignant tumor state are poorly understood. During the transition from benign tumors to malignant carcinoma, tumor cells need to repress differentiation and acquire invasive features. Using transcriptional profiling of cancer stem cells from benign tumors and malignant skin squamous cell carcinoma (SCC), we identified the nuclear receptor NR2F2...
According to Global Cancer Statistics 2020, lung cancer accounts for one in ten new cases (11.4%) and one in five cancer-related mortalities (18.0%), making it the deadliest and the second most frequently diagnosed cancer. Despite curative treatment, around 30–55% of patients relapse, primarily at distant sites, and 50% succumb to lung cancer, suggesting the early dissemination of malignant...
Cancer biophysics is an interdisciplinary field that combines the principles of physics, biology, and engineering to study the physical and mechanical aspects of cancer biology and its progression[1]. It focuses on understanding the physical forces, properties, and processes that govern cancer development, growth, invasion, metastasis, and response to treatment. Through the application of...
